From academia to start-up

It takes persistence to turn preclinical research into business. And it takes great teamwork to make it successful. In this episode of Theragnostic Talks we get to meet Dr Frances Johnson and Dr Michael Schultz. They founded Viewpoint Molecular Targeting, a radiopharmaceutical company with a theragnostic portfolio. Hear them talk about challenges along the way and why they believe in Alpha emitting isotopes. Enjoy!

Guests: Dr Frances Johnson, Dr Michael Schultz

By: Annette Andrén and Gustav Widar

Contact us: [email protected]

For more info, visit www.samnordic.se